Enlivex Therapeutics Ltd

Company Profile

Enlivex Therapeutics Ltd had its IPO on 1995-12-12 under the ticker symbol ENLV.

The company operates in the Healthcare sector and Biotechnology industry. Enlivex Therapeutics Ltd has a staff strength of 0 employees.

Stock update

Shares of Enlivex Therapeutics Ltd opened at $2.02 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.79 - $2.02, and closed at $1.94.

This is a +1.04% increase from the previous day's closing price.

A total volume of 72,020 shares were traded at the close of the day’s session.

In the last one week, shares of Enlivex Therapeutics Ltd have slipped by -17.45%.

Enlivex Therapeutics Ltd's Key Ratios

Enlivex Therapeutics Ltd has a market cap of $49.20 million, indicating a price to book ratio of 1.2047 and a price to sales ratio of 0.

In the last 12-months Enlivex Therapeutics Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-25020000. The EBITDA ratio measures Enlivex Therapeutics Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Enlivex Therapeutics Ltd’s operating margin was 0% while its return on assets stood at -19.81% with a return of equity of -43.78%.

In Q4, Enlivex Therapeutics Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Enlivex Therapeutics Ltd’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.7 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Enlivex Therapeutics Ltd’s profitability.

Enlivex Therapeutics Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.7132. Its price to sales ratio in the trailing 12-months stood at 0.

Enlivex Therapeutics Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$67.64 million

Total Liabilities

$6.61 million

Operating Cash Flow

$0

Capital Expenditure

$2.58 million

Dividend Payout Ratio

0%

Enlivex Therapeutics Ltd ended 2024 with $67.64 million in total assets and $0 in total liabilities. Its intangible assets were valued at $67.64 million while shareholder equity stood at $56.84 million.

Enlivex Therapeutics Ltd ended 2024 with $0 in deferred long-term liabilities, $6.61 million in other current liabilities, 2117000.00 in common stock, $-83025000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $47.82 million and cash and short-term investments were $48.12 million. The company’s total short-term debt was $653,000 while long-term debt stood at $0.

Enlivex Therapeutics Ltd’s total current assets stands at $52.33 million while long-term investments were $0 and short-term investments were $299000.00. Its net receivables were $647000.00 compared to accounts payable of $1.95 million and inventory worth $0.

In 2024, Enlivex Therapeutics Ltd's operating cash flow was $0 while its capital expenditure stood at $2.58 million.

Comparatively, Enlivex Therapeutics Ltd paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.94

52-Week High

$6.15

52-Week Low

$2.32

Analyst Target Price

$15

Enlivex Therapeutics Ltd stock is currently trading at $1.94 per share. It touched a 52-week high of $6.15 and a 52-week low of $6.15. Analysts tracking the stock have a 12-month average target price of $15.

Its 50-day moving average was $2.47 and 200-day moving average was $3.27 The short ratio stood at 5.69 indicating a short percent outstanding of 0%.

Around 1182.6% of the company’s stock are held by insiders while 975.3% are held by institutions.